Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Loading...
Thumbnail Image

Authors

Lawal, Ismaheel Opeyemi
Morgenstern, Alfred
Vorster, Mariza
Knoesen, Otto
Mahapane, Johncy
Hlongwa, Khanyisile N.
Maserumule, Letjie C.
Ndlovu, Honest
Reed, Janet D.
Popoola, Gbenga O.

Journal Title

Journal ISSN

Volume Title

Publisher

Springer

Abstract

Please read abstract in the article.

Description

Keywords

Targeted alpha therapy, Superscan, Skeletal metastases, Prostate cancer, Hematologic toxicity, Metastatic castration-resistant prostate cancer (mCRPC), Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617)

Sustainable Development Goals

Citation

Lawal, I.O., Morgenstern, A., Vorster, M. et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 49, 3581–3592 (2022). https://doi.org/10.1007/s00259-022-05778-w.